

11 May 2006

ProStrakan Group plc (the "Company")

Annual information update for period 16 June 2005 up to and including 11 May 2006.

This annual information update is required by and is being made pursuant to Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained herein (except as expressly set out herein). The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, nor the information referred to below, constitutes by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

1. Announcements made via RNS, a regulatory information service.

The following announcements were made by the Company via RNS, a regulatory information service, and may be viewed and downloaded from the London Stock Exchange website (www.londonstockexchange.com/marketnews).

<u>Date</u>	<u>Brief description of announcement</u>
11.05.06	Notice of results of AGM.
10.05.06	Retirement of Michael Bennett as a director.
13.04.06	Annual report and accounts for year ended 31 December 2005 and notice of AGM sent to FSA.
11.04.06	Notification of successful EU MRP conclusion for Tostrex (TM).
03.04.06	Notification of grant of awards and options to Executive Directors and PDMRs.
23.03.06	Notification of successful conclusion of EU MRP for Rectogesic (TM).
23.03.06	Notification of in-licensing agreement for Tabphyn (R).
23.03.06	Preliminary results for year ended 31 December 2005.
08.02.06	Information on the progress with Sancuso (TM) and Tostrex (R) development programmes.
25.01.06	Preliminary results to be announced on 23 March 2006 for year ending 31 December 2005.
24.01.06	Appointment of Alan Walker as a director.
29.12.05	Resignation of Roland Baron as a director.
21.12.05	Notification of in-licensing of EU Rights to Rapinyl (TM) and pre-close trading update.

05.12.05	Notification of executive directors and PDMR's invitation to participate in the Company's sharesave plan.
10.11.05	Notification of re-negotiation of improved EU rights to Rectogesic (R)
06.10.05	Notification of grant of awards and options to executive directors and PDMRs.
29.09.05	Notification of first EU launch of Tostrex (R) testosterone gel.
15.09.05	Interim results for six months ended 30 June 2005.
25.08.05	Notification of announcement of interim results 2005 on 15 September 2005 for 6 months ended 30 June 2005.
02.08.05	Notification of application to FSA and London Stock Exchange for additional listing by way of blocklisting.
26.07.05	Notification of application to FSA and London Stock Exchange for additional listing following exercise of share options.
01.07.05	FTSE Notification of inclusion of the Company in FTSE techMark All-Share index.
30.06.05	Announcement of appointment of Peter Cawdron as senior independent director.

2. Documents filed at Companies House

The documents listed below were filed with the Registrar of Companies in Scotland on or around the dates indicated. Copies of these documents may be obtained from Companies House, 37 Castle Terrace, Edinburgh EH1 2EB, email: enquiries@companieshouse.gov.uk or www.companieshouse.gov.uk

<u>Date</u>	<u>Document</u>
14.02.06	Form 288a – Appointment of Alan Walker as a director of the Company.
05.01.06	Form 288b – Resignation of Roland Baron as a director of the Company.
05.01.06	Form 288c – Change of particulars Wilson Totten.
05.01.06	Form 288c – Change of particulars Peter Allen.
05.01.06	Form 288c – Change of particulars Peter Cawdron.
05.01.06	Form 288c – Change of particulars Michael Asbury.
20.12.05	Form 287 – Change of address of registered office.
20.10.05	Form 288a – Appointment of Peter Cawdron as a director of the Company.
23.08.05	Form 363 – Annual return made up to 10 August 2005.
20.07.05	Form 88(2) – Return of allotment of 40,133 shares on exercise of share options.
08.07.05	Annual Accounts of the Group for the financial year end 31 December 2004.

07.07.05	Form 88(2) – Return of allotment of shares (bonus issue).
04.07.05	Form 88(3).
04.07.05	Form 88(2) – Return of allotment of 40,000,000 shares.
01.07.05	Print of the special resolution passed on 6 May 2005 (effective as at 16 June 2005).
01.07.05	Print of the new articles of association of the Company adopted by special resolution on 6 May 2005 (effective as at 16 June 2005).
01.07.05	Print of the memorandum of association of the Company altered by special resolution.
01.07.05	Form 122 – Share capital re-organisation.
01.07.05	Form 123 – Notice of increase in nominal capital.
01.07.05	Form 169 – Return by a company purchasing its own shares.
22.06.05	Form 353 – Register of members.

3. Documents filed with the Financial Services Authority

The following documents have been filed by the Company with the Financial Services Authority. These documents may be viewed at the UK Listing Authority's Document Viewing Facility at 25 The North Colonnade, Canary Wharf, London E14 5HS and are available on the Company's website at www.prostrakan.com.

<u>Date</u>	<u>Document</u>
11.05.06	AGM resolutions.
13.04.06	Annual report & accounts and notice of annual general meeting.
02.08.05	Application to FSA for additional listing by way of blocklisting.
26.07.05	Application to FSA for additional listing following exercise of share options.

Andrew F McLean, Company Secretary
ProStrakan Group plc